Table 1.
Patient characteristics.
| IPD AR | IPD TD | APD | P | Bonferroni post-hoc | |||
|---|---|---|---|---|---|---|---|
| AR vs. APD | AR vs. TD | APD vs. TD | |||||
| n | 20 | 20 | 20 | ||||
| Age (y) | 67.7 ± 9.7 | 65.6 ± 8.5 | 65.8 ± 8.3 | 0.706 | 1.000 | 1.000 | 1.000 |
| Gender (male:female) | 12:08 | 13:07 | 11:09 | 0.812* | |||
| Disease duration (y) | 6.6 ± 3.6 | 6.4 ± 3.2 | 5.2 ± 2.9 | 0.340 | 0.528 | 1.000 | 0.735 |
| H&Y | 2.9 ± 0.4 | 2.6 ± 0.4 | 3.1 ± 0.4 | 0.002 | 0.449 | 0.076 | 0.001 |
| MDS-UPDRS-3 | 22.1 ± 9.0 | 24.1 ± 9.6 | 38.4 ± 11.4 | 0.000 | 0.000 | 1.000 | 0.000 |
| PIGD | 4.4 ± 1.6 | 3.3 ± 1.7 | 7.4 ± 1.8 | 0.000 | 0.000 | 0.122 | 0.000 |
| LEDD (mg/d) | 591.6 ± 386.9 | 463.3 ± 378.4 | 712.3 ± 401.9 | 0.139 | 0.993 | 0.905 | 0.143 |
One-way ANOVA followed by Bonferroni post-hoc test,
*
Chi-squared test, Significance level p < 0.05. Bold numbers indicate significance.
H&Y, Hoehn and Yahr disease stage, MDS-UPDRS-3 (motor examination); LEDD, Levodopa equivalent daily dose; PIGD, Postural Instability and Gait Difficulty Score; IPD AR, akinetic-rigid subtype of Parkinson's disease; IPD TD, tremor-dominant subtype of Parkinson's disease; APD, Atypical Parkinsonian Disorders including MSA, Multiple system Atrophy; PSP, Progressive Supranuclear Palsy.